For informational purposes only — not investment advice

← Back to signals

TMO

LONGINSIDER SELL

THERMO FISHER SCIENTIFIC INC

Funds
4
Score
5.25
vs SPY
-16.1%
Stock return (since Q-end)
+0.2%
SPY return (since Q-end)
+16.3%
Current price
$492.51

News Summary

Negative

TMO reported Q1 2026 earnings beats on headline metrics (EPS +11%, revenue +6%) with raised full-year guidance ($24.64–$25.12 adjusted EPS, $47.3–$48.1B revenue), but underlying organic growth of only 1% disappointed investors, triggering a 7.5% intraday selloff. The company is executing a strategic pivot toward biopharma (Clario $8.9B acquisition, $1.075B microbiology divestiture) while facing macro headwinds in diagnostics and academia, with shareholder discontent over executive compensation also evident.

Red flags

  • Organic revenue growth of 1% significantly below consensus expectations, with weak diagnostics segment (-3% organic) and academic/government revenue declines
  • Stock down ~20% since January 31, 2026, trading at $473 vs. 52-week high of $644, indicating sustained investor skepticism
  • Shareholder advisory vote on executive compensation rejected with 214.5M votes against vs. 99.9M for—rare governance red flag signaling pay practice concerns
  • Microbiology divestiture ($1.075B sale to Astorg) dilutive by $0.15 EPS in first full year post-close; ongoing divestitures creating near-term EPS headwinds per analyst commentary
  • Muted macro conditions cited across U.S. and China markets; mid-single-digit revenue decline in diagnostics/healthcare segment due to weak respiratory season
  • Analyst price targets revised downward ~6% in past 3 months; Morgan Stanley cut target from $670 to $620 despite maintaining Overweight rating

Funds Buying (4)

FundManagerShares Held∆ SharesPosition ValueQoQStatus
Viking GlobalAndreas Halvorsen1.7M+875K$819.9B+110%Existing
D1 CapitalDan Sundheim725K+725K$356.4BNEW
Point72Steve Cohen354K+354K$173.8BNEW
Glenview CapitalLarry Robbins251K+27K$123.1B+12%Existing

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter.

Insider Activity

NameTitleTypeSharesPriceValueFiled
Pettiti GianlucaPresident & COOSELL400$462.66$0.19M2026-04-27